Therefore, GPX1 is a promising therapeutic target to overcome drug resistance induced by the T315I mutation, which provides a novel approach for BCR/ABL-T315I CML treatment by disturbing mitochondrial OXPHOS. Here, GPX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.